Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Piv... ( NEW YORK Feb. 11 /- Keryx Biophar...)

Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

Date:2/11/2008

NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals announced today that the last subject randomized into the SUN-Micro Phase 3 clinical trial has completed their scheduled 8 month visit. This milestone officially marks the completion of this pivotal clinical trial of its investigational drug Sulonex(TM) (sulodexide oral gelcap) in the treatment of subjects with type 2 diabetes and persistent microalbuminuria despite treatment with the maximum approved or tolerated dose of either an Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). This randomized, double-blind, placebo-controlled study enrolled 1,056 subjects at over 150 sites worldwide.

The Company anticipates being able to report top-line results from this study before the end of March 2008, and expects that the Collaborative Study Group will make a comprehensive scientific presentation of the data at a medical conference in the 2nd or 3rd quarter. The Company is targeting an NDA filing before year end.

"The completion of the Sulonex Phase 3 clinical program is an important and significant milestone for Keryx," stated Michael S. Weiss, Chairman and CEO of the Company, who continued, "We recognize and are grateful for the dedication, diligence and compliance exhibited by the Collaborative Study Group and the more than 1,000 patients who participated in what is considered to be the largest ever randomized study for type 2 diabetic patients with persistent microalbuminuria."

Commenting on the news, Edmund J. Lewis, MD, co-Principal Investigator of the Phase 3 Study remarked, "We would like to commend both our Investigators and their patients for their level of commitment towards the completion of this pivotal 8-month study, marking the culmination of critical research in a disease area for which there has not been a novel treatment option in almost 15 years. We look forward to assembling and analyzing the data from this study."

A
'/>"/>

SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO

Post Your Comments:

(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...

(Date:5/22/2013)... and TORONTO , May ... (OTCBB: GNBT) today announced three presentations demonstrating the superiority ... its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ... of the American Society of Clinical Oncology (ASCO) to ... May 31 through June 4, 2013. The ...

(Date:5/22/2013)... Mass. , May 22, 2013 Flagship ... firm focused on healthcare and sustainability, today announced ... as a Senior Partner. In this role, ... to portfolio companies. In addition to ... Mr. Bancel also serves as President and Chief ...

Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4 Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2 Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3

[0] Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance [0] Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine [0] Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures

... reduced signs and symptoms of SLE,disease at ... activity at 76 weeks-, ROCKVILLE, Md., June ... today announced the presentation of Phase 2,trial ... activity across multiple clinical,measures, was well tolerated ...

... - Neurogen,Corporation (Nasdaq: NRGN) today announced that data ... for NG2-73, the Company's,lead compound for the treatment ... SLEEP 2007 Annual Meeting of the Associated,Professional Sleep ... studies with NG2-73 in chronic insomnia patients,are currently ...

Cached Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 2 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 3 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 4 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 5

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...

(Date:5/22/2013)... Amy Norton HealthDay Reporter , , WEDNESDAY, May ... with athlete,s foot knows there is something about feet ... the first detailed "map" of the fungal groups that ... feet are the hottest neighborhood. It,s no secret ... such as bacteria, viruses and fungi, both outside and ...

(Date:5/22/2013)... People in the United States have been taking water ... much of the world, water shortages are normal and baths ... warns against taking water for granted and provides ways to ... in the United States. , Sharon Kleyne is host of ... live or by podcast on World Talk Radio, Voice America, ...

(Date:5/22/2013)... ID (PRWEB) May 22, 2013 Bodybuilding.com ... This Memorial Day (May 27, 2013) Bodybuilding.com will be donating ... of the amount. , “We are extremely grateful for ... the Armed Forces,” said Ryan DeLuca, CEO and founder of ... heroes who have sacrificed so much. Hire Heroes USA is ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Twenty student-led ... next year participating in an intensive startup accelerator designed ... products or services and create local jobs as part ... Each year the Edson initiative offers approximately 20 student ... space, mentorship and training to launch their for-profit, more-than-profit ...

[0] Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease [0] Scientists Map the Fungi on Your Feet [0] Water Advocate Sharon Kleyne Announces Water Conservation Appreciation [0] In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort

... , , , ... diagnostic services for veterinarians and pet owners, announced today it has ... Company and ProScan Imaging, both headquartered in Cincinnati. Financial terms were ... in Vienna, Va., Raleigh, N.C. and San Francisco and is the ...

... , Paul A. Markowski to Join ACCP as ... Aug. 10 The American College of Chest Physicians announced today that ... new Executive Vice President and CEO for the international medical specialty society. ... and CEO in the society,s 75-year history. , , ...

... Conn., Aug. 10 VION PHARMACEUTICALS, INC. (OTC ... the Oncologic Drugs Advisory Committee (ODAC) Meeting at which its ... , , The ODAC reviews and ... investigational human drug products for use in the treatment of ...

... Indiana University,s Center for Health Policy and Professionalism Research ... for individuals under age 65 remains virtually the same ... involved the government would be. Many ... insurance option, such as that being proposed by President ...

... human cancer tumors, the Ras protein literally "drives cells crazy," ... Life Sciences at Tel Aviv University. Prof. Kloog was the ... against pancreatic cancer, currently in clinical trials. Now, new research ... Pharmacology shows that the drug might be able to slow ...

... The Fountain of Life Group was in Canton, Ohio this weekend ... Pro Football Hall of Fame Yearbook. Fountain of Life is excited ... support of the Hall,s flagship publication. VaNu is featured in the ... Roger Staubach. , , The Pro Football Hall ...

Cached Medicine News:Health News:AnimalScan, LLC Acquires Iams Pet Imaging, LLC 2 Health News:American College of Chest Physicians Names New CEO 2 Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 2 Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 3 Health News:Americans remain divided on government involvement in health insurance, IU survey shows 2 Health News:Americans remain divided on government involvement in health insurance, IU survey shows 3 Health News:Taking the needle's sting out of diabetes 2 Health News:Fountain of Life Group Debuts VaNu at the Pro Football Hall of Fame Enshrinement Weekend 2

AnimalScan, LLC Acquires Iams Pet Imaging, LLC American College of Chest Physicians Names New CEO Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)Americans remain divided on government involvement in health insurance, IU survey shows Taking the needle's sting out of diabetes Fountain of Life Group Debuts VaNu at the Pro Football Hall of Fame Enshrinement Weekend

... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...

... Block and its operation software are ... of gene expression, genotyping, counting bacterial/viral ... microarray results. Exicycler is capable of ... such as protein-protein and protein-ligand, using ...

... easily converts any DNA Engine thermal cycler into ... with any of our user-changeable sample blocks. The ... it to keep pace with the evolving needs ... DNA Engine base units, new or existing. The ...

Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...

Medicine Products:

SmartCycler® 3200 System Exicycler™ Real-time Thermal Block Chromo 4 Four-Color Real-Time System Mx3000P Real-Time PCR System (110 volt) with Desktop Computer